Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105673934 | 10567393 | 4 | F | 20141020 | 20160530 | 20141106 | 20160708 | EXP | VE-AMGEN-VENSP2014084652 | AMGEN | 57.00 | YR | A | F | Y | 0.00000 | 20160708 | CN | VE | VE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105673934 | 10567393 | 1 | PS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 50 MG, WEEKLY | U | 103795 | 50 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 105673934 | 10567393 | 1 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 105673934 | 10567393 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 105673934 | 10567393 | Fungal skin infection | |
| 105673934 | 10567393 | Injection site erythema | |
| 105673934 | 10567393 | Injection site infection | |
| 105673934 | 10567393 | Injection site pruritus | |
| 105673934 | 10567393 | Nausea | |
| 105673934 | 10567393 | Oropharyngeal pain | |
| 105673934 | 10567393 | Vaginal haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 105673934 | 10567393 | 1 | 20141020 | 0 |